MARC details
| 000 -LEADER |
|---|
| fixed length control field |
05042cam a2200625 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
on1178868370 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OCoLC |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20221128212722.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS--GENERAL INFORMATION |
|---|
| fixed length control field |
m d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr ||||||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
140708s2014 nyu ob 001 0 eng |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
|---|
| LC control number |
2020679602 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
DLC |
| 019 ## - |
|---|
| -- |
890942048 |
| -- |
914433448 |
| -- |
923676305 |
| -- |
928196009 |
| -- |
992827141 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| ISBN |
9781633216013 |
| Qualifying information |
ebook |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| ISBN |
1633216012 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| Cancelled/invalid ISBN |
1633215849 |
| Qualifying information |
hbk. |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| Cancelled/invalid ISBN |
9781633215849 |
| Qualifying information |
hbk. |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
836693 |
| -- |
(N$T) |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(OCoLC)1178868370 |
| Canceled/invalid control number |
(OCoLC)890942048 |
| -- |
(OCoLC)914433448 |
| -- |
(OCoLC)923676305 |
| -- |
(OCoLC)928196009 |
| -- |
(OCoLC)992827141 |
| 042 ## - AUTHENTICATION CODE |
|---|
| Authentication code |
pcc |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MED |
| Subject category code subdivision |
085000 |
| Source |
bisacsh |
| 049 ## - LOCAL HOLDINGS (OCLC) |
|---|
| Holding library |
MAIN |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Macular edema : |
| Subtitle |
risk factors, treatment options and long-term outcomes |
| Statement of responsibility, etc |
|
| Medium |
[E-Book] |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
New York : |
| Name of producer, publisher, distributor, manufacturer |
Nova Publishers, |
| Date of production, publication, distribution, manufacture, or copyright notice |
[2014] |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Physical description |
1 online resource. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
computer |
| Media type code |
c |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
online resource |
| Carrier type code |
cr |
| Source |
rdacarrier |
| 490 1# - SERIES TITLE |
|---|
| Series statement |
Eye and Vision Research Developments |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references and index. |
| 505 0# - CONTENTS |
|---|
| Contents |
MACULAR EDEMA: RISK FACTORS, TREATMENT OPTIONS AND LONG-TERM OUTCOMES; MACULAR EDEMA: RISK FACTORS, TREATMENT OPTIONS AND LONG-TERM OUTCOMES; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: MANAGEMENT OF DIABETIC MACULAR EDEMA BY INTRAVITREAL ANTIANGIOGENIC DRUGS; ABSTRACT; INTRODUCTION; ROLE OF VEGF; PEGAPTANIB (MACUGEN�, PFIZER OPHTHALMICS); RANIBIZUMAB (LUCENTIS�, GENENTECH, NOVARTIS); BEVACIZUMAB (AVASTIN�, ROCHE, GENENTECH); AFLIBERCEPT (EYLEA�, BAYER, REGENERON PHARMACEUTICALS); TREATMENT PROTOCOLS; CONCLUSION; REFERENCES. |
| 505 8# - CONTENTS |
|---|
| Contents |
Chapter 2: MANAGEMENT OF MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION BY INTRAVITREAL BEVACIZUMABABSTRACT; INTRODUCTION; PATHOGENESIS; TREATMENT; ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR; ANTIANGIOGENIC TREATMENT; INTRAVITREOUS BEVACIZUMAB IN BRVO; INTRAVITREOUS BEVACIZUMAB IN CRVO; ANTI-VEGF IN ISCHEMIC RETINA; TREATMENT PROTOCOLS; CONCLUSION; REFERENCES; Chapter 3: POSTOPERATIVE CYSTOID MACULAR EDEMA IN DIABETIC PATIENTS: PROPHYLAXIS AND MANAGEMENT; ABSTRACT; INTRODUCTION; PATHOGENESIS; PREOPERATIVE CARE; MANAGEMENT; REFERENCES; Chapter 4: MANAGEMENT OF DIABETIC MACULAR EDEMA. |
| 505 8# - CONTENTS |
|---|
| Contents |
ABSTRACTINTRODUCTION; MANAGEMENT OF SYSTEMIC RISK FACTORS; LASER PHOTOCOAGULATION FOR DME; PHARMACOLOGICAL DME TREATMENT; COMBINATION THERAPY FOR DME MANAGEMENT; SURGICAL TREATMENT OF DME; TREATMENT GUIDELINES OF DME; CONCLUSION; REFERENCES; Chapter 5: CURRENT MANAGEMENT OF CHRONIC DIABETIC MACULAR OEDEMA; ABSTRACT; INTRODUCTION; EPIDEMIOLOGY OF DIABETIC MACULAR OEDEMA; PATHOPHYSIOLOGY OF CHRONIC DIABETIC MACULAR OEDEMA; INVESTIGATIONS FOR DMO; LASER TREATMENT IN THE MANAGEMENT OF CHRONIC DIABETIC MACULAR OEDEMA; ANTI-VEGF THERAPIES. |
| 505 8# - CONTENTS |
|---|
| Contents |
INTRAVITREAL STEROIDS TO TREAT CHRONIC DIABETIC MACULAR OEDEMADMO TREATMENT ALGORITHM; FUTURE MANAGEMENT OPTIONS; CONCLUSION; REFERENCES; Chapter 6: MACULAR EDEMA IN IMPORTANT TROPICAL INFECTIONS; ABSTRACT; INTRODUCTION; MACULAR EDEMA IN SOME IMPORTANT TROPICAL INFECTIONS; CONCLUSION; REFERENCES; Chapter 7: CYSTOID MACULAR EDEMA: A DIFFICULT OCULAR DISORDER TO CURE; ABSTRACT; INTRODUCTION; MACULAR HOLE; TREATMENT OF MACULAR EDEMA; CASE REPORT; DISCUSSION; CONCLUSION; ACKNOWLEDGMENTS; REFERENCES; INDEX. |
| 520 ## - ABSTRACT |
|---|
| Abstract |
Macular edema is a serious eye disorder that can be seen in many conditions. Central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) are frequent causes of decreased central visual acuity (VA) related to the appearance of macular edema (ME) and ischemia. This book discusses the risk factors, treatment options and long-term outcomes of macular edema. Some of the topics discussed include the management of diabetic macular edema; management of macular edema secondary to retinal vein occulsion by intravitreal bevacizumab; and macular edema in important tropical infections. |
| 590 ## - LOCAL NOTE (RLIN) |
|---|
| Local note |
WorldCat record variable field(s) change: 650 |
| 650 #0 - SUBJECT HEADINGS |
|---|
| Subject term |
Macula lutea |
| General subdivision |
Diseases. |
| 650 #0 - SUBJECT HEADINGS |
|---|
| Subject term |
Edema. |
| 650 #0 - SUBJECT HEADINGS |
|---|
| Subject term |
Macula lutea. |
| 650 #0 - SUBJECT HEADINGS |
|---|
| Subject term |
Eye |
| General subdivision |
Diseases. |
| 650 #2 - SUBJECT HEADINGS |
|---|
| Subject term |
Macula Lutea |
| 650 #2 - SUBJECT HEADINGS |
|---|
| Subject term |
Edema |
| 650 #2 - SUBJECT HEADINGS |
|---|
| Subject term |
Eye Diseases |
| 700 1# - ADDED PERSONAL NAME |
|---|
| Added personal author |
Davison, Earl, |
| Relator term |
editor. |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
Eye and Vision Research Developments. |
| 856 40 - ONLINE RESOURCE |
|---|
| Uniform Resource Identifier |
<a href="https://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=836693">https://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=836693</a> |
| Link text |
Kingston Hospital NHS Foundation Trust OpenAthens account holders click here for access |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Suppress in OPAC |
Do not Suppress in OPAC |
| 588 ## - SOURCE OF DESCRIPTION NOTE |
|---|
| Source of description note |
Description based on print version record and CIP data provided by publisher. |
| 938 ## - |
|---|
| -- |
ProQuest Ebook Central |
| -- |
EBLB |
| -- |
EBL3024678 |
| 938 ## - |
|---|
| -- |
ebrary |
| -- |
EBRY |
| -- |
ebr10918995 |
| 938 ## - |
|---|
| -- |
EBSCOhost |
| -- |
EBSC |
| -- |
836693 |
| 938 ## - |
|---|
| -- |
YBP Library Services |
| -- |
YANK |
| -- |
11975933 |
| 994 ## - |
|---|
| -- |
92 |
| -- |
N$T |